Pediatric Targeted Therapy 2.0 (PTT2.0)– refining diagnosis and analyzing targets in progressive and relapsed pediatric malignancies

Pediatric Targeted Therapy 2.0 (PTT2.0)– refining diagnosis and analyzing targets in progressive and relapsed pediatric malignancies - PTT2.0

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011707

Enrollment

200

Registered

2017-02-20

Start date

2017-02-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive or relapsed pediatric malignancies

Interventions

Group 1: Molecular diagnosis using DNA-methylation array and GPS (Gene-Panel-Sequencing) in tumor FFPE blocks of the recurrence, progressing pediatric tumor, or the preceding primary tumor). For comp

Eligibility

Sex/Gender

All

Age

0 Years to 22 Years

Inclusion criteria

Inclusion criteria: • Age: 0 to <22 years • Diagnosis: Recurrence or progression of any pediatric tumor • signed ICF including information on whether germline information should be passed on to the patient and/or her/his legal guardians • sufficient tumor material and peripheral blood sample

Exclusion criteria

Exclusion criteria: • primary diagnosis of a pediatric tumor

Design outcomes

Primary

Measure	Time frame
• to determine the incidence of integrated molecular diagnoses including targetable alterations (DNA-methylation array and GPS) in the studied population	—

Secondary

Measure	Time frame
• to determine the turnover time (time in days from receipt of complete submission to mailing of a report) • to determine the frequency and type of a) targeted therapies initiated based upon the integrated molecular diagnosis, or b) other therapies initiated after receiving results from the PTT2.0 Analysis Explorative • OS (overall survival) and EFS (event free survival) of patients after PTT2.0 analysis, a) with or b) without targeted therapies initiated based upon the integrated molecular diagnosis	—

Measure

Time frame

• to determine the turnover time (time in days from receipt of complete submission to mailing of a report) • to determine the frequency and type of a) targeted therapies initiated based upon the integrated molecular diagnosis, or b) other therapies initiated after receiving results from the PTT2.0 Analysis Explorative • OS (overall survival) and EFS (event free survival) of patients after PTT2.0 analysis, a) with or b) without targeted therapies initiated based upon the integrated molecular diagnosis

—

Countries

Germany

Contacts

Public ContactSabine Brokmeier

Department of Pediatric Oncology and Hematology KiTZ Clinical Trial Unit (ZIPO) and Brain Tumors

zipo.ambulanz@med.uni-heidelberg.de06221 56 37082

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026